Kestra Medical Technologies (KMTS) Q1 2027 earnings review
Margin leverage proves the model, but costs widen the burn
Kestra posted 60% revenue growth to $31.0 million, pushing gross margins up by 10.8 points year-over-year to 56.5%. The company raised its full-year revenue guide by $4 million to $141 million. Despite the top-line beat, the aggressive commercial buildout widened the GAAP net loss to $44.1 million and the adjusted EBITDA loss to $24.0 million.
⚖️ Verdict: 🟢 Bullish
The case is better — a bullish verdict — and the reason is the relentless gross margin expansion proving the rental model's unit economics work at scale. The raised revenue guide confirms the sales force investment is effectively capturing share in the wearable defibrillator market, overshadowing the absolute cash burn in the short term.
What the print did not settle is when the margin leverage will actually outrun the commercial investments to generate cash: the adjusted EBITDA loss worsened year-over-year because operating expenses swallowed all the incremental gross profit. Next quarter's operating expense growth against the new top-line base will read on the actual path to profitability.
🐂 Bull Case
Unlocking the Rental Model's Leverage
Kestra is proving the inherent unit economics of its wearable medical device leasing model. Gross margin expanded 10.8 points year-over-year to reach 56.5%, marking the tenth consecutive quarter of sequential improvement. Because the core hardware sits on the balance sheet as capital expenditure, adding new patients through existing insurance contracts directly drops the incremental revenue to the gross profit line.
Management attributed the expansion to volume leverage and a higher mix of in-network patients, a structural shift from the 70% in-network mix the company reported at its IPO a year ago. The trajectory suggests the company remains on a direct path toward its stated goal of 70% long-term gross margins, shielding the core business model from pricing compression.
Raised the Full-Year Guide on Top of 60% Growth
First-quarter revenue of $31.0 million grew 60% year-over-year, leading management to raise the fiscal 2027 revenue guide from $137 million to $141 million. The new target represents 48.2% annual growth over fiscal 2026, meaning the aggressive territory expansion executed over the last four quarters is successfully capturing share from the incumbent in the wearable cardioverter defibrillator market.
🐻 Bear Case
Commercial Expense Outpaces Gross Profit Growth
Despite gross profit nearly doubling to $17.5 million, the adjusted EBITDA loss worsened from $19.4 million a year ago to $24.0 million this quarter. The gap points directly to the cost of Kestra's aggressive commercial strategy: SG&A consumed 156.1% of revenue in the quarter. While that is down from 174.1% a year ago, the absolute dollar increase in SG&A (+$14.6 million) severely outran the gross profit dollars gained (+$8.6 million).
This cuts against the standing narrative that the company's strong capital position naturally bridges the gap to cash-flow breakeven without strain. Kestra is paying heavily to take market share; until the sequential additions to operating expense moderate, the exceptional gross margin leverage will not flow through to the bottom line.
Omission of Core Operational Metrics
The earnings release stripped out three vital key performance indicators that management consistently disclosed throughout fiscal 2026: prescription volumes, the in-network patient mix percentage, and the conversion rate.
Without the raw prescription count, it is impossible to cleanly separate how much of the 60% revenue growth came from pure volume versus improved reimbursement pricing. Removing visibility into the in-network mix obscures the runway remaining for the gross margin leverage thesis.
👓 Other Themes
Bolstered Liquidity Defers Dilution Risk
Kestra ended the quarter with $244.7 million in cash and investments and reported total liquidity of approximately $320 million inclusive of an undrawn term loan. This buffer effectively removes near-term financing risk as the company absorbs the elevated cash burn required to double its sales territories.
💲 Other KPIs
Up 70% year-over-year, representing 21.9% of revenue.
The cash burn from operations expanded from $26.3 million a year ago, reflecting the widening net loss and working capital investments required for the commercial ramp.
🔮 Guidance
Raised the prior view by $4 million to 48.2% year-over-year growth. The guide implies 45.2% growth for the remaining three quarters of the fiscal year (derived).
❓ Key Questions
Missing Operational KPIs
Why were prescription counts, in-network mix percentages, and conversion rates omitted from this quarter's release, and will they be provided going forward?
Profitability Timeline
With gross margins now exceeding 56%, at what quarterly revenue scale do you expect the absolute dollar additions to SG&A to moderate enough to reach adjusted EBITDA breakeven?
Commercial Footprint
How many active sales territories did you end Q1 with, and what is the target territory count by the end of fiscal 2027?